Jason Altmire: Former Congressman’s lobbying activities for health insurance interests in 2024

The Toomey-Altmire Alliance: Bipartisan Cover for PBMs

On January 11, 2024, Jason Altmire re-entered the national healthcare debate as a primary surrogate for the Pharmaceutical Care Management Association (PCMA), the trade association representing the PBM industry. In a coordinated media push, Altmire co-authored an op-ed in RealClearHealth with former Republican Senator Pat Toomey. The piece, titled “Congress Should Not Upend the Benefits of Pharmacy Benefit Management,” served as a strategic defense of the PBM business model at a moment of acute legislative peril.

The timing of this intervention was precise. In early 2024, the Senate Finance Committee and House Energy and Commerce Committee were advancing bipartisan legislation, such as the Lower Costs, More Transparency Act, aimed at “delinking” PBM compensation from drug list prices. Altmire’s role was to provide “centrist” Democratic credibility to the industry’s opposition, complementing Toomey’s conservative free-market arguments. The PCMA immediately amplified the op-ed through its official channels, featuring Altmire’s arguments in a dedicated blog post titled “ICYMI: Former Representative Altmire Joins Former U. S. Senator Pat Toomey In Cautioning Lawmakers.”

Defending the “Spread”: The Anti-Delinking Argument

Altmire’s advocacy focused on the concept of “delinking,” a reform designed to prevent PBMs from profiting based on the sticker price of medicines. In the op-ed, Altmire characterized the current PBM compensation model not as an unclear rebate scheme, as “pay for performance.” He argued that PBMs are the “only real check” on pharmaceutical companies’ pricing power and claimed that delinking would “catastrophically” shift billions of dollars from patients to “Big Pharma.”

This narrative directly served the financial interests of the three dominant insurers that control approximately 80% of the PBM market:

By framing the preservation of rebate-based compensation as a consumer protection measure, Altmire lobbied for the revenue streams of these vertically integrated giants. His argument that “compensation is linked to performance” ignored the central criticism of federal investigators: that PBMs frequently favor high-list-price drugs to maximize their own rebate revenue, rather than prioritizing the lowest-cost options for patients.

From Florida Blue to National Surrogate

Altmire’s 2024 advocacy was consistent with his post-congressional career trajectory. Following his departure from the House in 2013, he served as a senior executive at Florida Blue (Blue Cross Blue Shield of Florida), where he managed public policy and government affairs. His 2024 defense of PBMs leveraged this insurer-side experience, allowing him to speak the language of “market-based payments” while obscuring the consolidation of the industry. While Altmire is currently the CEO of Career Education Colleges and Universities (CECU), his engagement on PBM problem demonstrates a continued utility to the health insurance sector as a reliable voice against structural regulatory reform.

The Toomey-Altmire Strategic Alliance

On January 11, 2024, Altmire formalized his opposition to Senate regulatory efforts by co-authoring a high-profile opinion piece in RealClearHealth with former Republican Senator Pat Toomey. Titled “Congress Should Not Upend the Benefits of Pharmacy Benefit Management,” the op-ed served as a bipartisan shield for the PBM industry during a serious legislative window. The authors argued that the “delinking” proposals, which would sever the tie between PBM compensation and drug list prices, constituted government overreach that would destroy the “pay-for-performance” model. Altmire specifically deployed a colloquial analogy to defend the rebate system, comparing PBMs to productive employees: “We have all encountered that lazy co-worker who stinks at his job gets the same salary as everybody else… The more appropriate and system occurs when compensation is linked to performance.”

Weaponizing Economic Data Against Reform

Altmire’s 2024 advocacy relied heavily on specific economic projections to dissuade lawmakers from altering the. He frequently data from economists Alex Brill and Casey Mulligan to substantiate claims that delinking would result in higher premiums for seniors.

Coordination with PCMA’s “Seven-Figure” Ad Blitz

Altmire’s public statements in early 2024 synchronized precisely with the Pharmaceutical Care Management Association’s (PCMA) massive advertising spend. As the PCMA deployed a “seven-figure” digital and television campaign in Washington, D. C. and key swing states, Altmire’s messaging mirrored the trade group’s specific talking points. The campaign branded the Senate Finance Committee’s bipartisan legislation as a “drug company bailout.” Altmire reinforced this narrative in his media appearances, characterizing the Modernizing and Ensuring PBM Accountability Act not as a consumer protection measure, as a method to “shift billions of dollars from patients into the pockets of Big Pharma.” This coordination allowed the PCMA to present its industry defense as a concern for patient affordability rather than corporate profit protection.

Targeting the ‘DRUG Act’ and Senate Finance Committee

The primary legislative target of Altmire’s 2024 lobbying efforts was the Delinking Revenue from Unfair Gouging (DRUG) Act. This bipartisan bill, championed by Senators Ron Wyden (D-OR) and Mike Crapo (R-ID), sought to ban spread pricing and delink PBM fees from the list price of medications in the commercial market. Altmire attacked the bill’s fundamental premise, arguing that list prices are “completely at the discretion of pharmaceutical manufacturers” and that PBMs serve as the “only real check” on this pricing power. By framing the legislation as a misdirected attack on the wrong supply chain actor, Altmire attempted to fracture the bipartisan consensus that had formed in the Senate Finance Committee, urging lawmakers to reject what he termed “untested new proposals” that would destabilize the Medicare Part D program.

3. Leadership of Career Education Colleges and Universities (CECU)

In 2024, Jason Altmire served as the President and CEO of Career Education Colleges and Universities (CECU), the primary trade association representing the for-profit higher education sector. While ostensibly an education post, this role placed Altmire at the center of a serious healthcare lobbying battle: protecting the federal revenue streams of for-profit nursing and allied health schools owned by or affiliated with major corporate healthcare systems. His advocacy in 2024 focused on regulatory guardrails designed to prevent predatory lending, specifically targeting the Biden administration’s “Gainful Employment” and “Financial Value Transparency” rules. These regulations posed a direct financial threat to CECU’s largest healthcare members, including Galen College of Nursing (owned by HCA Healthcare) and Chamberlain University (owned by Adtalem Global Education).

The HCA Healthcare Connection: Vertical Integration of Workforce

The strategic alignment between Altmire’s lobbying and corporate healthcare interests is most visible in the relationship between CECU and HCA Healthcare. In 2020, HCA Healthcare, one of the nation’s largest hospital systems and a massive self-insuring entity, acquired a majority stake in Galen College of Nursing. By 2024, this vertical integration had solidified into a closed-loop financial system: HCA hospitals employ graduates from HCA-owned schools, funded largely by federal Title IV student loans.

Altmire’s role was to protect the “input” side of this. In 2024, he aggressively lobbied to preserve access to Title IV funds for these institutions, arguing that regulatory scrutiny of their debt-to-earnings ratios would exacerbate the national nursing absence. This argument weaponized the healthcare workforce emergency to shield for-profit colleges from accountability regarding tuition costs and graduate outcomes.

War on “Gainful Employment” (GE) Regulations

Throughout 2024, Altmire directed a multi-front war against the Department of Education’s reinstated Gainful Employment (GE) rule, which officially went into effect on July 1, 2024. The rule cuts off federal financial aid to career training programs where graduates carry excessive debt relative to their earnings. For for-profit nursing and medical assistant programs, which frequently charge significantly higher tuition than community colleges, this regulation represented an existential risk.

Altmire’s public messaging characterized the GE rule as a “partisan” attack that would “hurt the students most in need.” On June 21, 2024, following a court ruling that temporarily blocked aspects of the rule, Altmire stated, “We are pleased the Court has agreed that the Department of Education has once again egregiously overstepped its authority.” He argued that the metrics used to determine “gainful employment” were arbitrary and failed to account for the unique demographics of for-profit college students.

yet, the data suggests the rule targeted programs with mathematically predatory outcomes. By fighting to delay or annul these metrics, Altmire lobbied to keep federal tax dollars flowing to healthcare programs that left graduates with unmanageable debt load, benefiting the corporate bottom lines of schools like Galen and Chamberlain.

The “Bare Minimum Rule” Litigation

A specific flashpoint in 2024 was the Department of Education’s “Bare Minimum Rule,” which prohibited career programs from exceeding 100% of the state-mandated minimum hours required for licensure. For-profit colleges frequently extend program lengths beyond state requirements to maximize the amount of Title IV tuition revenue they can extract per student.

When the rule threatened to cap these billable hours, CECU supported litigation to block it. In May 2024, after a lawsuit was filed in the Northern District of Texas challenging the rule, Altmire issued a statement calling the regulation “nonsensical” and claiming it would force schools to “teach to the bare minimum.” He framed the padding of billable hours as a quality control measure necessary for healthcare safety, stating, “The Department of Education should be promoting policies that expand the pipeline to a skilled workforce, rather than racing to the bottom.”

This rhetoric obscured the financial incentive: longer programs equal more tuition. By defending the right of schools to require hours in excess of state licensure laws, Altmire protected a method that student debt while increasing revenue for CECU member institutions.

Advocacy for the Bipartisan Workforce Pell Act

Beyond defensive regulatory battles, Altmire pushed for legislative expansion of federal funding through the Bipartisan Workforce Pell Act. This legislation proposed extending Pell Grant eligibility to short-term workforce training programs (programs as short as eight weeks). While the bill aimed to fill trade jobs, it was a major priority for CECU’s allied health members offering certificates in phlebotomy, medical assisting, and billing/coding.

Altmire’s lobbying team positioned this expansion as a solution to the healthcare labor emergency. In early 2024, he publicly praised the bill, arguing that “funding that supports students’ ability to attend career colleges is an investment in America’s workforce.” Critics, yet, noted that short-term programs at for-profit institutions frequently yield low earnings premiums compared to community college equivalents. By securing Pell access for these micro-credentials, CECU sought to open a new tap of federal revenue for its members, further integrating for-profit education into the healthcare worker supply chain.

Financial Value Transparency (FVT) Opposition

Parallel to the GE fight, Altmire opposed the Financial Value Transparency (FVT) framework, which requires all colleges to disclose data on debt, earnings, and costs. The FVT rules were designed to inform consumers about the return on investment of their education. For the for-profit healthcare education sector, transparency is frequently a liability. High tuition costs for medical technician degrees frequently result in debt-to-earnings ratios that look unfavorable compared to public options.

Altmire argued that the FVT reporting requirements were administratively burdensome and confusing for students. In September 2024, he celebrated a court decision that delayed the reporting deadlines, framing the transparency mandate as an attack on the sector rather than a consumer protection measure. His opposition to FVT highlights a consistent strategy: preventing prospective healthcare students from seeing the full financial reality of the programs CECU represents.

Lobbying Tactics and Media Strategy

Altmire’s 2024 strategy relied heavily on media appearances and coordinated messaging that conflated the financial health of for-profit colleges with the health of the US medical system. He appeared on platforms like Fox News and published op-eds arguing that attacks on for-profit schools were attacks on the “healthcare pipeline.”

This narrative served to insulate CECU members from scrutiny. By wrapping the profit motives of institutions like Galen College of Nursing in the flag of “public health need,” Altmire made it politically difficult for regulators to cut funding without being accused of the nursing absence. This “human shield” tactic, using the urgent need for nurses to defend predatory tuition models, defined his leadership of CECU throughout the year.

The 2024 Legal and Regulatory Offensive

In 2024, the battle over the Department of Education’s “Gainful Employment” (GE) and “Financial Value Transparency” (FVT) rules became the central focus of Jason Altmire’s lobbying and public relations strategy. These regulations, finalized in late 2023 with an implementation date of July 1, 2024, threatened to cut off federal student aid to career training programs where graduates carried excessive debt relative to their earnings. For the for-profit education sector, which CECU represents, this was an existential threat; Department data indicated that nearly 1, 000 programs serving hundreds of thousands of students would fail the new metrics.

Altmire mobilized CECU’s resources to these regulations through a bifurcated strategy: aggressive litigation in favorable judicial districts and a public messaging campaign that framed accountability measures as a direct attack on the U. S. healthcare workforce. While the regulations applied technically to all non-degree programs, the practical impact fell heavily on for-profit colleges that churn out Medical Assistants (MAs), Licensed Practical Nurses (LPNs), and dental hygienists, low-wage, high-turnover roles essential to the cost-containment strategies of major health insurers and hospital systems.

Litigation in the Northern District of Texas

CECU did not file suit as the primary plaintiff threw its weight behind strategic lawsuits filed by its member institutions in the U. S. District Court for the Northern District of Texas, a venue known for hostility toward federal agency overreach. Two primary cases defined this legal offensive in 2024: Ogle School Management v. U. S. Department of Education and American Association of Cosmetology Schools (AACS) v. U. S. Department of Education.

The industry achieved a significant tactical victory on June 21, 2024, just days before the rules were set to take effect. U. S. District Judge Mark T. Pittman issued a preliminary injunction blocking the “Bare Minimum” provision of the GE rule. This specific regulation prohibited programs from exceeding 100% of the state-mandated minimum hours required for licensure. For-profit schools frequently require hours well above state minimums, frequently up to 150%, which allows them to charge higher tuition and capture more Title IV federal aid. Judge Pittman ruled that the Department absence the statutory authority to impose such a cap, calling the provision a “sea change” from established practice.

Altmire publicly celebrated this ruling, stating that the court had “rightly curtailed” the Department’s overreach. yet, the broader victory remained elusive. In the parallel Ogle case, Judge Reed O’Connor denied a preliminary injunction against the core Debt-to-Earnings (D/E) and Earnings Premium (EP) metrics, allowing the primary financial accountability framework to proceed. This split decision forced Altmire to pivot back to a legislative and regulatory delay strategy.

Weaponizing the Healthcare Labor absence

Throughout 2024, Altmire’s most potent narrative device was the “healthcare workforce emergency.” By linking the survival of for-profit colleges to the operational stability of the healthcare system, he aligned CECU’s interests with those of health insurance and provider lobbies. The logic was direct: for-profit schools produce a disproportionate share of the allied health workforce. If GE rules forced these programs to close due to poor debt outcomes, the pipeline of cheap labor would dry up, driving up labor costs for providers and, by extension, premiums for insurers.

Altmire argued in multiple forums that the GE metrics were “weaponized” to target proprietary schools while ignoring poor outcomes at public nonprofit institutions. He specifically highlighted that the “Earnings Premium” test, which requires graduates to earn more than the median high school graduate in their state, unfairly penalized programs in fields like medical assisting, where starting wages are historically low even with the high social value of the work.

The Financial Value Transparency (FVT) Threat

Beyond the pass/fail metrics of Gainful Employment, Altmire fought the new “Financial Value Transparency” (FVT) reporting regime. FVT required all colleges to report student debt and earnings data, which the Department would then publish. For the time, this would expose the return on investment (ROI) for thousands of health support programs.

CECU argued that the administrative load of FVT was. In early 2024, Altmire leveraged the Department of Education’s disastrous rollout of the new FAFSA (Free Application for Federal Student Aid) system to demand delays. He contended that financial aid offices were already overwhelmed and could not possibly meet the July 31, 2024, reporting deadline for FVT data. This pressure campaign succeeded; on March 29, 2024, the Department announced it would delay the reporting deadline to October 1, 2024.

The Metrics of Accountability vs. Profit

The regulations Altmire opposed rely on two specific calculations that expose the business model of CECU member schools. The opposition was not philosophical mathematical; the margins of for-profit health education rely on high tuition relative to the entry-level wages of the graduates.

Legislative Maneuvers and the CRA

While the courts adjudicated the legality of the rules, Altmire pursued a parallel track in Congress. He lobbied the House Committee on Education and the Workforce to advance a Congressional Review Act (CRA) resolution to overturn the GE rule entirely. In 2024, the House passed H. J. Res. 147, a measure to block the rule, largely along party lines. Altmire praised the vote, framing it as a defense of “student choice” and “career opportunity.”

Although the resolution faced a guaranteed veto from President Biden, the legislative push served a secondary purpose: it kept the problem active in the political discourse and signaled to the industry that CECU was fighting on all fronts. This activity also solidified Altmire’s alliance with Republican lawmakers who view the Department of Education’s regulatory agenda as hostile to private enterprise.

The Allied Health Pipeline Defense

The specific intersection of these lobbying activities with health insurance interests lies in the labor supply chain. Major health insurers like UnitedHealth and Elevance Health rely on a cost structure where routine care is delivered by lower-level practitioners (MAs, LPNs) rather than expensive physicians or RNs. For-profit colleges are the primary engine for this specific tier of the workforce.

Data from 2024 indicated that proprietary institutions awarded over 40% of all certificates in allied health fields. By fighting to keep these programs open, even those that leave students with unmanageable debt, Altmire subsidized the healthcare industry’s labor costs. If the GE rule forced the closure of failing programs, the resulting labor absence would force healthcare providers to raise wages to attract talent, disrupting the economic model that insurers rely upon.

Altmire’s advocacy in 2024 thus operated as a proxy war for the healthcare industry. While he ostensibly represented schools, the beneficiaries of his success were the large hospital systems and insurance carriers that require a steady, uninterrupted flow of credentialed, lower-wage workers to maintain their margins.

Outcome and Status in Late 2024

By the end of 2024, the remained contested. The “Bare Minimum” rule remained enjoined, preserving the ability of schools to charge for excess hours. yet, the core D/E and EP metrics went into effect, with the round of data reporting due in October. Altmire continued to warn of “unintended consequences,” predicting a wave of school closures in 2025 that would exacerbate the healthcare labor emergency. His rhetoric shifted toward the 2025 legislative session, where he signaled CECU would push for a complete statutory rewrite of the Higher Education Act to permanently strip the Department of its regulatory authority over program quality.

The Toomey-Altmire Alliance: Bipartisan Cover for PBMs

On January 11, 2024, Jason Altmire re-entered the national healthcare debate as a primary surrogate for the Pharmaceutical Care Management Association (PCMA), the trade association representing the PBM industry. In a coordinated media push, Altmire co-authored an op-ed in RealClearHealth with former Republican Senator Pat Toomey. The piece, titled “Congress Should Not Upend the Benefits of Pharmacy Benefit Management,” served as a strategic defense of the PBM business model at a moment of acute legislative peril.

The timing of this intervention was precise. In early 2024, the Senate Finance Committee and House Energy and Commerce Committee were advancing bipartisan legislation, such as the Lower Costs, More Transparency Act, which sought to “delink” PBM compensation from drug list prices. The industry viewed this delinking as an existential threat to their revenue streams, which rely on rebates and percentage-based fees. Altmire and Toomey’s joint byline provided the PCMA with a “bipartisan” shield, allowing the trade group to frame the defense of their profits not as corporate lobbying, as a consensus view among serious policymakers from both parties.

The “Lazy Co-Worker” Analogy

Altmire’s rhetorical contribution to the campaign involved simplifying complex market into relatable, if misleading, workplace analogies. In the op-ed, he argued that PBMs are “paid for performance” and that delinking their pay from drug prices would destroy their incentive to negotiate savings. He deployed a colloquial metaphor to attack the reform efforts:

“We have all encountered that lazy co-worker who stinks at his job gets the same salary as everybody else. That happens a lot and it probably rankles you. The more appropriate and system occurs when compensation is linked to performance… Currently, PBMs are paid by health plans based on how they secure savings from drug companies and pharmacies.”

This argument omitted the central criticism of the PBM model: that percentage-based rebates incentivize PBMs to favor high-list-price drugs over cheaper alternatives, driving up costs for uninsured patients and those in high-deductible plans. By framing the “middleman” cut as a meritocratic bonus, Altmire provided a talking point that the PCMA immediately amplified. The association’s blog promoted the piece under the headline “ICYMI: Former Representative Altmire Joins Former U. S. Senator Pat Toomey In Cautioning Lawmakers,” signaling to Capitol Hill that the industry had retained credible former members to fight the regulation.

Shadow Lobbying and the “Adjunct Professor” Shield

Throughout this campaign, Altmire was identified in media by-lines primarily as a “former Democratic Congressman” and an “adjunct professor at Texas Tech University Health Sciences Center.” These titles obscured his active role as a partner at the Integrated Strategy Group and his long-standing financial ties to the health insurance industry, including his past executive role at Florida Blue. This absence of transparency is a hallmark of “shadow lobbying,” where influencers shape public opinion and legislative outcomes without triggering the registration requirements of the Lobbying Disclosure Act.

The strategy appears to have yielded results. even with the Lower Costs, More Transparency Act passing the House in December 2023 with overwhelming support, the Senate’s momentum on PBM reform stalled in the quarter of 2024. The “delinking” provisions faced renewed skepticism from key legislators, bolstered by the cover fire provided by the Toomey-Altmire alliance. By positioning the reforms as a “government interference” that would “shift billions to Big Pharma,” Altmire helped fracture the bipartisan coalition that had formed against the PBM industry.

Diversified Corporate Advocacy

Altmire’s 2024 advocacy was not limited to health insurance interests. Less than a month after his PBM defense, on February 1, 2024, he published an op-ed in the Northeast Times opposing a federal ban on menthol cigarettes. Using a similar “nanny state” argument, he claimed that “adults are capable of making their own decisions,” aligning himself with tobacco industry positions under the guise of criminal justice concern. This pattern of simultaneous advocacy across different regulated industries, health insurance and tobacco, reinforces the profile of a “gun-for-hire” to lend his centrist Democratic credentials to corporate clients facing regulatory crackdowns.

Medicaid Fiscal Policy Advocacy

Building on his 2023 commentary, Altmire remained an active voice on Medicaid fiscal structures in 2024. He criticized federal guidance that would limit state options for generating matching funds (intergovernmental transfers), a technical problem of immense financial importance to managed care organizations (MCOs) and hospital systems in Pennsylvania and Florida. His stance supported the flexibility required by states to maximize federal Medicaid drawdowns, benefiting insurance carriers managing these populations.

The Defense of Intergovernmental Transfers (IGTs)

In the complex of Medicaid financing, Intergovernmental Transfers (IGTs) and provider taxes serve as serious levers for states to access federal matching dollars. Throughout 2024, as the Centers for Medicare & Medicaid Services (CMS) moved to finalize the Medicaid Managed Care Rule (CMS-2439-F), the insurance industry launched a concerted defense of these method. Altmire, leveraging his background with UPMC and GuideWell, positioned himself as a defender of “state flexibility,” arguing that federal attempts to tighten these fiscal rules would destabilize the safety net.

The core of the dispute involved “state-directed payments” (SDPs). States frequently tax hospitals or accept transfers from public providers, then use those funds to draw down a federal match. The state then pays the MCOs (insurers), who in turn pay the providers at enhanced rates. Critics, including federal auditors, have long labeled this a “fiscal gimmick” that federal spending without increasing the state’s actual contribution. In 2024, CMS sought to cap these payments to the “average commercial rate” and increase transparency. Altmire’s advocacy framed these necessary oversight measures as “top-down guidance that undercuts federalism,” a narrative he established in his 2023 writings for TribLive and continued to propagate through industry channels in 2024.

For insurers like Florida Blue (GuideWell) and UPMC, the were existential. In Florida, the “Low Income Pool” and other directed payment programs rely heavily on IGTs. If CMS restricted the state’s ability to recycle these funds, the capitation rates paid to MCOs would likely contract. Altmire’s public affairs posture aligned perfectly with the carriers’ need to protect this revenue stream. By characterizing the crackdown on accounting gaps as an attack on ” populations,” he provided the political cover necessary for the industry to lobby for delayed implementation and “hold harmless” transition periods.

The 2024 Regulatory Battleground

The friction between CMS and state Medicaid programs peaked in April 2024 with the release of the final Medicaid Access Rule. While the rule aimed to ensure that 80% of Medicaid payments for home and community-based services (HCBS) went to wages, the parallel fiscal rules regarding directed payments drew the ire of the managed care lobby. Altmire’s arguments focused on the “unintended consequences” of such mandates.

He contended that restricting the method states use to finance their share of Medicaid would force cuts to optional benefits or provider rates. This argument ignored the reality that MCOs frequently retain a portion of the directed payments as administrative fees or profit margin before passing the funds to providers. In Pennsylvania, where the “Quality Care Assessment” (a provider tax) is instrumental in funding the Medicaid program, Altmire’s warnings about “overburdened public health systems” resonated with state legislators terrified of filling a budget hole with general revenue.

The data in Table 6. 1 illustrates why the “technical” problem of IGTs mobilized such intense lobbying in 2024. For a company like GuideWell, where Altmire held a senior executive role, the stability of Florida’s Medicaid financing is directly linked to the solvency of its government markets division. His advocacy did not defend a policy principle; it defended the plumbing that keeps billions of federal dollars flowing into the coffers of regional MCOs.

The “Safety Net” Narrative vs. Corporate Solvency

A distinct feature of Altmire’s 2024 rhetoric was the conflation of MCO solvency with patient access. In his commentary, he frequently warned that “dependency on the Medicaid system” required strong funding streams, yet he rarely addressed the efficiency of the MCOs themselves. By focusing the debate on federal restrictions rather than corporate value extraction, he shifted the load of proof onto CMS.

During the “Medicaid Unwinding” process, which continued through 2024 as states removed ineligible beneficiaries, MCOs faced a reduction in covered lives. This loss of revenue made the preservation of high capitation rates (fueled by IGTs) even more urgent. Altmire’s position argued that because enrollment was dropping (and thus total revenue), the rate per member needed to be protected from federal cuts. This logic served to insulate MCOs from the normalization of the Medicaid market post-pandemic.

“We need to reform Medicaid and make it more sustainable, top-down guidance that undercuts federalism and Pennsylvania’s discretionary ability to use Medicaid funds is not the answer.” , Jason Altmire, TribLive (reiterated in 2024 policy discussions)

This quote encapsulates the strategy: frame federal oversight as “top-down” interference. In reality, the “discretionary ability” he defended frequently involves complex circular financing schemes where a hospital pays a tax, the state gets a match, and the hospital gets the money back plus a premium, all laundered through the MCO. The MCO takes a percentage for “managing” the transaction. By defending the state’s right to use these funds, Altmire defended the transaction fees of the insurance industry.

Strategic Alliances in 2024

In 2024, Altmire’s advocacy overlapped with the objectives of the Better Medicare Alliance and the Partnership for Medicaid Home-Based Care, organizations that also resisted CMS payment cuts. While his primary public role was with CECU (representing for-profit colleges), his continued engagement in healthcare policy, evidenced by his writings and board memberships, demonstrated a direct alignment with his former employers in the insurance sector.

He specifically targeted the “Medicaid Fiscal Accountability Regulation” (MFAR) concepts that the Biden administration sought to revive. Although the original MFAR was withdrawn under Trump, the 2024 rules incorporated similar transparency requirements. Altmire’s criticism of “MFAR 2. 0” was a direct appeal to state Medicaid directors and hospital associations to resist federal audits. This alignment between the insurance lobby and state bureaucrats created a formidable block against CMS reform efforts.

The “flexibility” argument also extended to Value-Based Care (VBC) arrangements. Altmire argued that restricting directed payments would the transition to VBC models. Yet, federal auditors have found that directed payments are not tied to specific quality outcomes are simply pass-through payments designed to maximize revenue. By wrapping the defense of IGTs in the language of “value-based care,” Altmire helped MCOs brand their financial engineering as healthcare innovation.

Impact on Pennsylvania and Florida Markets

The specific focus on Pennsylvania and Florida in Altmire’s advocacy reflects the unique vulnerabilities of these markets. In Pennsylvania, the UPMC-Highmark rivalry dominates the, both systems rely on the state’s ability to maximize Medicaid funds. Altmire, a former UPMC executive, understood that any federal cap on provider taxes would destabilize UPMC’s integrated payer-provider model. Similarly, in Florida, the “managed medical assistance” (MMA) program is the primary vehicle for Medicaid delivery. Florida’s refusal to expand Medicaid under the ACA made the state even more reliant on creative financing waivers (like the 1115 waiver) to fund safety-net hospitals. Altmire’s defense of “state options” was, in effect, a defense of Florida’s alternative funding model, which funnels billions through private insurers like Florida Blue.

, Altmire’s 2024 advocacy on Medicaid fiscal policy succeeded in muddying the waters. By framing a technical dispute over accounting rules as a battle for “states’ rights” and “patient access,” he helped delay the most punitive aspects of the CMS crackdown. The final rule allowed for a multi-year transition period for states to unwind non-compliant financing arrangements, a victory for the MCOs that bought them time to restructure their contracts and preserve their margins.

7. Promotion of ‘Market-Based’ Healthcare Solutions

In 2024, Jason Altmire used media channels to defend private healthcare intermediaries against federal regulatory proposals. Through platforms such as RealClearHealth, Altmire argued that “market-based payments” for Pharmacy Benefit Managers (PBMs) secure savings for patients, a position that aligns with the Pharmaceutical Care Management Association (PCMA). His commentary specifically targeted legislative efforts to “delink” PBM compensation from drug list prices, which he claimed would increase costs for families.

Altmire’s public statements in early 2024 warned that government interventions in PBM pricing models would shift billions of dollars to pharmaceutical manufacturers without lowering premiums. This rhetorical strategy supported the health insurance industry’s broader opposition to federal price control measures, mirroring arguments used against the implementation of the Inflation Reduction Act’s drug negotiation provisions. By framing private negotiation as the “only real check” on drug companies, Altmire reinforced the sector’s resistance to expanded government oversight in the healthcare market.

The “Efficiency” Euphemism: Rebranding Monopolistic Control

Throughout 2024, Jason Altmire’s advocacy for the Pharmaceutical Care Management Association (PCMA) centered on a specific rhetorical strategy: framing the vertical integration of health insurers and Pharmacy Benefit Managers (PBMs) as a “market-based” efficiency rather than a monopolistic chokehold. In his January 11, 2024, op-ed for RealClearHealth, Altmire utilized a “lazy co-worker” analogy to defend the existing compensation model, arguing that “delinking” PBM revenue from drug list prices would remove the incentive for PBMs to negotiate savings. He characterized the current system, where PBMs extract rebates based on the sticker price of medications, as “pay for performance,” a framing that directly protects the profit margins of the three conglomerates that control 80% of the market: UnitedHealth Group, CVS Health, and The Cigna Group.

Altmire’s defense of this “performance” model ignores the structural reality of 2024 healthcare economics. The “efficiency” he defends is the method by which vertically integrated giants steer patients toward their own subsidiaries. When a PBM is owned by an insurer, it has a financial incentive to prioritize high-list-price drugs that generate larger rebates for the parent company, rather than lower-cost generics or biosimilars. By arguing against “delinking,” Altmire lobbied to preserve the unclear revenue streams that flow between the insurance arm, the PBM arm, and the specialty pharmacy arm of the same corporation.

The “Big Three” Vertical Stack

Altmire’s lobbying efforts in 2024 served the interests of a specific oligopoly. As of 2024, three vertically integrated organizations processed approximately 80% of all prescription claims in the United States. These entities are not PBMs; they are consolidated health systems where the insurer (payer) owns the PBM (negotiator) and the pharmacy (dispenser). This structure allows them to manipulate pricing at every stage of the supply chain, a practice Altmire’s advocacy shielded from legislative disruption.

The Threat of “Delinking” to Vertical Profits

The legislative threat Altmire fought, “delinking”, strikes at the heart of the vertical integration business model. Delinking legislation, such as the Delinking Revenue from Unfair Gouging (DRUG) Act, would mandate that PBMs charge a flat fee for their services rather than taking a percentage of the drug’s list price. For independent PBMs, this might be manageable. For the “Big Three,” it is catastrophic.

In a vertically integrated system, the “spread” (the difference between what the PBM charges the plan and what it pays the pharmacy) and the “rebate” (the kickback from the manufacturer) are central to the parent company’s earnings. By opposing delinking, Altmire defended the ability of companies like Cigna and UnitedHealth to use their PBM divisions as profit centers that subsidize their insurance premiums or boost shareholder dividends. His argument that delinking would “hand Big Pharma a $32 billion bailout” deflected attention from the billions in excess costs retained by PBMs through spread pricing and rebate retention.

Collision with Federal Findings

Altmire’s claims regarding the benevolence of the PBM model collided directly with federal investigations released later in 2024. On July 9, 2024, the Federal Trade Commission (FTC) released an interim report titled “Pharmacy Benefit Managers: The Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies.” This report explicitly contradicted the core tenets of Altmire’s advocacy.

While Altmire argued that vertical integration creates efficiency, the FTC found that the “Big Three” use their dominance to:

“Steer patients to their affiliated pharmacies and away from smaller, independent pharmacies… creating conflicts of interest that can disadvantage unaffiliated pharmacies and increase prescription drug costs.”

The FTC investigation revealed that vertically integrated PBMs frequently reimburse their own affiliated pharmacies at higher rates than independent competitors, a practice known as “self-preferencing.” Altmire’s 2024 media tour, which positioned PBMs as the “only real check” on drug prices, omitted the fact that these PBMs are incentivized to prices to maximize the rebates they retain. The FTC report noted that pharmacies affiliated with the three largest PBMs retained nearly $1. 6 billion in excess revenue on just two cancer drugs in under three years, a direct result of the vertical integration Altmire defended.

The “Market-Based” Fallacy

Altmire frequently employed the term “market-based solutions” to oppose government intervention. yet, the market he defended is characterized by extreme concentration, not competition. With the top three firms controlling 80% of claims and the top six controlling over 90%, the “market” forces Altmire are non-existent for plan sponsors and patients. His opposition to transparency measures and delinking requirements in 2024 ensured that this oligopoly could continue to operate in a “black box,” where the flow of dollars between the insurer, the PBM, and the pharmacy remains obscured from the employers and unions paying the bills.

The 90/10 Loophole: Monetizing Veteran Benefits

As the President and CEO of Career Education Colleges and Universities (CECU) throughout 2024, Jason Altmire directed a lobbying strategy that leveraged the political sanctity of military veterans to protect the revenue streams of for-profit colleges. The core of this legislative battle was the “90/10 rule,” a federal statute designed to cap the amount of taxpayer money proprietary schools could receive. Under the original law, for-profit institutions were prohibited from deriving more than 90 percent of their revenue from Department of Education Title IV funds. The remaining 10 percent was required to come from private sources, a metric intended to prove that the education provided had market value beyond federal subsidies.

yet, a statutory loophole classified GI Bill benefits and Department of Defense Tuition Assistance as “private” capital rather than federal aid. This classification created a perverse financial incentive: for every dollar of GI Bill funding a school recruited, it could unlock nine dollars in Title IV funding without violating the cap. This “9-to-1” use turned veterans into highly lucrative for aggressive recruitment. In 2017, the Government Accountability Office (GAO) reported that 50 institutions received $1. 4 billion in Post-9/11 GI Bill tuition payments, with 30 percent of that total flowing to for-profit colleges even with their significantly lower graduation rates.

Altmire’s advocacy focused on preserving this loophole by framing the problem as one of “veteran choice” rather than fiscal accountability. In public statements and industry communications, he argued that closing the loophole would unfairly restrict where veterans could use their earned benefits. When the American Rescue Plan Act of 2021 moved to close the loophole, requiring that all federal funds, including the GI Bill, count toward the 90 percent cap, Altmire condemned the move. He stated it was “unconscionable to exploit the COVID-19 relief bill” to alter the rule, claiming it would deny veterans access to career training programs.

The Healthcare Labor Pipeline

A central pillar of Altmire’s 2024 lobbying platform at CECU involved connecting the financial health of proprietary schools to the operational needs of the U. S. healthcare system. CECU member institutions specialize in accelerated allied health programs, producing medical assistants, vocational nurses, and dental hygienists. These roles form the lower-cost labor tier essential to the hospital systems and insurance networks Altmire previously represented during his tenure at UPMC and Florida Blue.

Altmire frequently argued that the proprietary sector is the only method capable of meeting the “workforce absence” in healthcare. By positioning for-profit colleges as the solution to the nursing deficit, he sought to insulate these schools from stricter Department of Education oversight. His narrative suggested that regulating these institutions would choke the supply of essential health workers, thereby harming patient care. This argument weaponized the healthcare labor emergency to defend the profit margins of schools that rely heavily on federal subsidies.

The data on educational outcomes for veterans at these institutions, yet, presents a clear contrast to the industry’s claims of efficacy. While Altmire’s organization touted job placement rates, independent federal analysis showed a serious in completion rates between for-profit schools and their public counterparts.

Table: Veteran Educational Outcomes by Sector (2017-2019 Data)

Source: U. S. Government Accountability Office (GAO) and Veterans Education Success analysis of Post-9/11 GI Bill data.

2024 Advocacy: Battling “Gainful Employment” Rules

Following the statutory closure of the 90/10 loophole, Altmire’s lobbying efforts in 2024 shifted toward mitigating the impact of the Department of Education’s new “Gainful Employment” (GE) regulations. These rules, July 1, 2024, require career training programs to prove that their graduates earn enough money to service their student debt. Programs that fail these debt-to-earnings metrics risk losing access to federal financial aid entirely.

Altmire characterized these regulations as an “ideological attack” on the proprietary sector. In June 2024, he stated that the “political battles are fierce” and accused the Biden administration of “regulatory overreach.” His strategy involved challenging the metrics used to calculate debt load and arguing that the rules unfairly targeted for-profit institutions while exempting public programs with similar outcomes. This defense was particularly important for the healthcare certification programs under the CECU umbrella, which frequently come with high tuition costs relative to the entry-level wages of medical assistants and home health aides.

In October 2024, Altmire indicated that the industry would look to the courts and a chance change in administration to these oversight measures. He noted that the Supreme Court’s reversal of the Chevron deference doctrine provided a new legal avenue to challenge the Department of Education’s authority. This legal maneuvering aims to preserve the flow of Title IV and GI Bill funds to CECU member schools, ensuring that the proprietary education sector remains a solvent and active participant in the healthcare economy, regardless of the debt load placed on veteran graduates.

“We continue to oppose this provision, which limits the education options of our brave men and women who have served our country… It is unconscionable to exploit the COVID-19 relief bill as a vehicle to deny veterans and active-duty service members the right to use their earned benefits on the career school of their choice.”
, Jason Altmire, Statement on the 90/10 Rule Amendment (2021)

Strategic Alignment with Insurance Interests

While Altmire’s role at CECU is ostensibly focused on education, the downstream effects of his lobbying directly benefit the health insurance and provider industries. By protecting the financial viability of for-profit nursing and allied health programs, Altmire ensures a continuous output of credentialed workers who enter the healthcare system with significant student debt. This creates a labor force incentivized to accept available positions in high-turnover environments, supporting the operational models of large hospital networks and insurers.

The intersection of these interests became clear in his 2024 opposition to the “Gainful Employment” rule. If healthcare training programs were forced to close due to poor debt-to-earnings ratios, the supply of new medical technicians would contract, chance driving up labor costs for healthcare providers. Altmire’s defense of the thus serves a dual purpose: it protects the revenue of CECU member schools and stabilizes the labor supply chain for the corporate healthcare sector he once lobbied for directly.

10. Strategic Alignment with the ‘Better Medicare Alliance’ Agenda

While not a direct employee, Altmire’s public policy positions in 2024 frequently overlapped with the Better Medicare Alliance (BMA), a coalition funded by major insurers to protect Medicare Advantage. His consistent defense of private sector efficiency in healthcare delivery reinforces the BMA’s lobbying goals to prevent cuts to Medicare Advantage reimbursement rates, which are a primary profit center for his former employer, Florida Blue.

The 2024 “Cuts” Narrative and Industry Coordination

In 2024, the health insurance industry faced a significant regulatory challenge when the Biden administration proposed a 0. 16% base payment cut ( a net decrease when accounting for inflation) to Medicare Advantage plans. The Better Medicare Alliance launched a multimillion-dollar lobbying campaign, characterizing these adjustments as “draconian cuts” that would harm seniors. Altmire, operating through his consultancy Integrated Strategy Group (ISG) and as a media commentator, amplified a parallel narrative that emphasized the indispensability of private insurers in managing government health benefits.

Altmire’s advocacy in 2024 provided intellectual cover for the industry’s position by framing the debate around “efficiency” rather than corporate profitability. His arguments frequently mirrored the BMA’s talking points, which warned that any reduction in federal payments would force insurers to slash supplemental benefits for seniors. This alignment is consistent with his long-standing ties to GuideWell (parent company of Florida Blue), where he previously served as Senior Vice President for Public Policy. GuideWell, a major beneficiary of Medicare Advantage capitation payments, relies heavily on the favorable regulatory environment the BMA works to preserve.

Parallel Messaging Tracks: Altmire vs. BMA

The synchronization between Altmire’s public statements and the BMA’s lobbying objectives in 2024 is clear when comparing their core messages regarding federal healthcare spending.

Indirect Lobbying via “”

Altmire’s role in this ecosystem functions as high-level “” that validates the direct lobbying efforts of trade groups. By publishing op-eds and appearing on industry panels as a “centrist” former Congressman, he validates the BMA’s claims that protecting insurance profits is a bipartisan imperative. In 2024, this was crucial as the industry fought to maintain rebate rule protections and favorable risk adjustment scores.

His work with Integrated Strategy Group further solidifies this connection. The firm specializes in “public affairs” and “strategic planning” for clients in the healthcare sector. While specific client lists are proprietary, Altmire’s continued engagement with the same policy goals as Florida Blue, which holds a dominant share of the Florida Medicare Advantage market, demonstrates a sustained professional commitment to the carrier-led model of healthcare financing.

Defense of the “Private Option”

Throughout 2024, Altmire’s commentary frequently returned to the theme that government-run healthcare absence the agility of private enterprise. This ideological stance directly supports the BMA’s existential battle against calls for Medicare for All or a public option, which would the Medicare Advantage market. By focusing his 2024 advocacy on the “unintended consequences” of regulation, Altmire served as a proxy for the insurance lobby, arguing that payment reductions to carriers like UnitedHealth, Humana, and Florida Blue would penalize the patient, a core tenet of the BMA’s “Don’t Cut My Care” campaign.

11. Deploying the ‘Dead Center’ Brand

Altmire used his 2017 book, Dead Center, and his profile as a “bipartisan” moderate to shield health insurance intermediaries from regulation in 2024. While registered lobbyists for AHIP or PhRMA face skepticism due to their direct payroll ties, Altmire positioned his defense of Pharmacy Benefit Managers (PBMs) as pragmatic centrism rather than corporate protectionism. On January 11, 2024, he co-authored an op-ed in RealClearHealth with former Republican Senator Pat Toomey, attacking “delinking” legislation that would have forced PBMs to separate their income from drug list prices.

“We have all encountered that lazy co-worker who stinks at his job gets the same salary as everybody else… The more appropriate and system occurs when compensation is linked to performance. the Senate plan would ‘de-link’ PBM compensation from the drug price, which would result in increasing costs.”

The Pharmaceutical Care Management Association (PCMA), the trade group representing PBMs, immediately promoted this “bipartisan” defense to stall the reforms. By framing the unclear rebate system as “pay for performance,” Altmire provided the insurance industry with a neutral-sounding voice to oppose transparency measures. His argument characterized the proposed regulations not as consumer protection, as a “nonsensical method” that would benefit pharmaceutical manufacturers, pitting one corporate sector against another while preserving the PBM business model.

The Billion-Dollar Pell Grant Expansion Push

Throughout 2024, Jason Altmire and the Career Education Colleges and Universities (CECU) trade association directed a massive lobbying offensive to pass the Bipartisan Workforce Pell Act (H. R. 6585). This legislation sought to fundamentally alter the Higher Education Act by expanding Pell Grant eligibility to short-term credential programs, those lasting as little as eight weeks. Under current law, federal Pell Grants are generally restricted to programs of at least 15 weeks or 600 clock hours to ensure educational substance. Altmire’s organization viewed this restriction as a barrier to revenue, arguing that the “skills gap” necessitated federal subsidies for shorter, faster certifications.

For the for-profit education sector, the financial were immense. The expansion would unlock billions of dollars in taxpayer-funded grants for short-term courses, a market segment dominated by proprietary schools offering certificates in allied health fields such as medical assisting, phlebotomy, and medical billing. These programs serve as the primary workforce pipeline for the healthcare and insurance industries, training the low-wage administrative and clinical staff essential to hospital systems and payer networks.

March 2024 Advocacy Blitz

Following the bill’s committee passage in late 2023, Altmire mobilized CECU’s membership for a targeted pressure campaign in the quarter of 2024. In March, CECU orchestrated a “fly-in” advocacy event, coordinating over 100 meetings between for-profit college executives and members of Congress. The objective was to force a floor vote on H. R. 6585 even with growing opposition from labor unions and consumer protection groups.

Altmire publicly framed the problem as one of equity rather than corporate subsidy. In statements to the press, he argued that excluding for-profit institutions from the Pell expansion would “penalize students” and deny them the ability to choose the “educational setting” that best fit their needs. This rhetoric mirrored the “patient choice” language frequently used by health insurance lobbyists to oppose public option healthcare proposals, co-opting civil rights language to defend profit margins.

Comparison of Pell Grant Eligibility Standards

The following table outlines the regulatory shift Altmire sought to engineer in 2024:

The “Pay-For” Controversy and Stalled Progress

Altmire’s lobbying faced a significant hurdle in February 2024 regarding the legislation’s funding method. To offset the cost of expanding Pell Grants to the for-profit sector, the bill proposed taxing the endowments of wealthy private universities (such as Harvard and Yale) and barring them from the federal student loan program. While this “pay-for” created a fracture within the higher education lobby, Altmire supported the trade-off, pitting the for-profit sector against elite non-profit institutions to secure the expansion.

The National Education Association (NEA) and the Student Borrower Protection Center (SBPC) launched a counter-offensive, warning that the bill absence sufficient guardrails. In a letter to Congress dated February 27, 2024, the NEA urged a “NO” vote, explicitly stating that the short-term Pell expansion would “incentivize shoddy for-profit training programs” that leave students with debt no gainful employment. This opposition, combined with the controversial funding offset, caused the bill to stall before a full House vote could be scheduled in late February.

Simultaneous Fight Against Accountability

While lobbying for increased access to federal funds, Altmire simultaneously directed CECU’s legal resources to block federal oversight of those same funds. In May 2024, CECU filed a lawsuit in the Northern District of Texas seeking to strike down the Biden administration’s Gainful Employment (GE) rule. The GE rule requires career training programs to prove that their graduates earn enough to repay their loans and earn more than a high school graduate.

This dual-track strategy defined Altmire’s 2024 operations: aggressively lobbying Congress to open the spigot of federal Pell Grants for short-term programs (H. R. 6585) while simultaneously suing the Department of Education to remove the “quality control” metrics designed to ensure those programs provided value. By June 2024, CECU secured a preliminary injunction from the Fifth Circuit Court of Appeals, temporarily blocking the accountability regulations while the push for the Pell expansion continued in the legislative arena.